Navigation Links
Oncothyreon appoints Scott Peterson as Vice President of Research and Development
Date:6/15/2009

SEATTLE, June 15 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced the appointment of Scott Peterson, Ph.D., as Vice President, Research and Development at Oncothyreon. In this position, Dr. Peterson will be responsible for overseeing those pre-clinical and non-clinical research and development activities that will support the advancement of the Company's pipeline of oncology product candidates into late phase clinical trials.

"Scott brings an extensive background in cancer drug development to his new role at Oncothyreon," said Robert L. Kirkman, M.D, President and Chief Executive Officer. "His prior experience in small molecule drug development includes work with protein kinases that will be especially relevant to PX-866, our inhibitor of PI-3 kinase for which we recently presented encouraging preliminary Phase 1 data at the American Society of Clinical Oncology. His broad knowledge of cancer biology and drug targets will also be helpful in our ongoing search for new product candidates. We are delighted to have him join our team."

"I am very pleased to join Oncothyreon and excited about the opportunity to contribute to the further development of the Company's intriguing pipeline of targeted anti-cancer drug candidates," said Dr. Peterson. "I believe Oncothyreon's diverse pipeline of therapeutic vaccines, such as Stimuvax(R), and targeted small molecules, including PX-866 and PX-478, create multiple opportunities for future success. I am looking forward to contributing to that future."

Dr. Peterson joins Oncothyreon from Zymogenetics, Inc., Seattle, Washington, where he has served as Director and Department Head, Oncology Research, since 2007. In that capacity he has led a group of scientists engaged in antibody target discovery and drug candidate identification in oncology. From 1999 until 20
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
2. Oncothyreon announces closing of $11.1 million registered direct financing
3. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
4. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
5. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
6. Oncothyreon reports first quarter 2009 financial results
7. Oncothyreon regains compliance with NASDAQ listing requirements
8. Oncothyreon to present at Invest Northwest 2009
9. Oncothyreon reports full year and fourth quarter 2008 financial results
10. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
11. Oncothyreon to present at BIO CEO & Investor Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced ... Resverlogix have approved the resolutions relating to: (i) ... 5,600,000 units at a price of $2.67 per ... comprised of one common share and 0.075358 common ... CAD$15 million; and (ii) the amendment to Resverlogix,s ...
(Date:6/30/2015)...  Today, Americord Registry, one of the fastest growing cord ... a partner at Kirkland & Ellis LLP, as the newest ... http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled about ... Martin Smithmyer , CEO of Americord. "He brings a wealth ... assist Americord,s growth and vision." Andrew Horne ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares proposed to ... shares (including shares of unvested restricted stock). On June 29, 2015, the last trading ... Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , The tender offer ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... its Phase 1/2 clinical trial of RCT-01, being ... tendinosis, has been enrolled and their tissue biopsy ... RCT-01 is comprised of non-bulbar dermal sheath (NBDS) ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... Conn., Jan. 8 The readers of The IN ... the biopharmaceutical and medical device industries, have selected a ... Pharmaceuticals, RNA interference alliance with Takeda Pharmaceuticals .More than 2,500 ... led the polling from start to finish among the 13 ...
... InteKrin Therapeutics, Inc.,will present at the 27th Annual ... on Tuesday, January 13, 2009, to be held at ... President and,CEO Denny Lanfear will present at the conference. ... ): , InteKrin Therapeutics is ...
... AcelRx Pharmaceuticals, Inc.,announced today it has hired ... In this new position, Dr. Skowronski will be ... providing medical input,and review of clinical development strategy. ... company,s Chief Medical Officer. , ...
Cached Biology Technology:The IN VIVO Blog Selects First Annual 'Deal of the Year' 2InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13 2
(Date:6/11/2015)... Daon, a global leader in mobile ... Mobile Authentication Platform v4.0 has been FIDO Certified™.  ... industry consortium launched in 2013 to revolutionize online ... In order to receive certification, a company,s products ... tests that measure compliance and ensure interoperability among ...
(Date:6/9/2015)... , June 09, 2015 Research ... addition of the "Gesture Recognition & Touchless ... (Consumer Electronics, Automotive, & Others), Product (Biometric & ... to 2020" report to their offering. ... market is expected to reach $ 23.55 Billion ...
(Date:6/5/2015)... -- Intrexon Corporation ("Intrexon") (NYSE: XON ), a leader ... the final distribution ratio relating to its previously announced ... Oncology, Inc. ("ZIOPHARM") (NASDAQ: ZIOP ) common stock ... as a pro rata dividend on shares of Intrexon ... Intrexon common stock ("Warrants"), outstanding on June 4, 2015, ...
Breaking Biology News(10 mins):Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 3Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 4
... Today, the International Osteoporosis Foundation (IOF) recognized the outstanding ... Hong Kong, Malaysia and Pakistan. The IOF Young ... to the five highest scored abstracts submitted to the ... of 40. The Meeting, which closes today at the ...
... theory of evolution suggests that present-day organisms evolved from ... reshaped some of the enzymes that help complete chemical ... other life forms. Now a University of Iowa ... forms of the enzyme "dihydrofolate reductase" as it occurred ...
... HOUSTON (Dec. 12, 2013) Blending more ethanol into ... risk that toxic or even explosive gases may find their ... Those problems would likely occur in buildings with cracked ... spills. Vapors that rise from contaminated groundwater can be sucked ...
Cached Biology News:Young investigators awarded for research excellence at Hong Kong meeting 2UI researcher studies evolution on the molecular level 2Ethanol blends carry hidden risk 2Ethanol blends carry hidden risk 3
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
... Inventory Storage Racks for Standard 3" ... fit all makes and models of ... of high quality stainless steel and ... stainless steel or plastic boxes. ...
... cell-based assays utilize the membrane-permeant ester ... negatively charged fluorescent beta-lactamase substrates, CCF2 ... enter the cell, where cleavage by ... into their negatively charged forms, thereby ...
... ISOQUANT(R) Isoaspartate Detection Kit is intended for ... proteins and peptides, which can result from ... rearrangement of aspartic acid residues during storage ... depend on the monitoring of charge differences ...
Biology Products: